How AVM develops instruments directly with surgeons

Most surgical instruments fail not because they are badly made, but because they were designed by people who do not use them. This is the structural problem that AVM's product development process is built to solve.

Every new product at AVM begins in an operating theatre. Not in a CAD application, not in a marketing brief — in a procedure, where a surgeon notices something the existing instruments cannot do, or cannot do well. A retractor that slips on a particular angle of approach. A forceps whose tip is too coarse for the tissue plane. A needle holder whose ratchet releases under thumb pressure during a critical suture. These are the small, tactile signals that tell us a product idea exists.

The next step is conversation. Our development team — many of whom are clinicians themselves or have spent careers in surgical product engineering — sits with the surgeon and walks the procedure step by step. We ask what the instrument is fighting against. We ask what the surgeon would do differently if the tool let them. We ask what they have improvised, modified, or borrowed from another speciality. This is where vague frustration becomes a specification.

From specification, we move into prototype. AVM's manufacturing facilities in New Delhi are configured to produce one-off and small-batch instruments quickly. A first prototype can be in a surgeon's hand within weeks of the initial conversation. It is rarely correct. Iteration is the point.

Our German engineering collaboration plays a structural role here. Material selection, heat treatment, edge geometry, and articulation tolerances all benefit from the same precision standards used in instruments produced for the European market. When an Indian neurosurgeon describes a problem, the tooling that responds to it is benchmarked against the most demanding manufacturing standards in the world. ANI Instruments, our partner brand of products made in Germany, gives us a direct pathway into those standards and that vocabulary.

Iteration continues until the instrument behaves the way the surgeon needed it to behave — and then continues for two or three rounds beyond that, because the most useful feedback often arrives only after a clinician has used a prototype in five or ten consecutive procedures. Real performance is measured under real fatigue, under unfamiliar anatomy, under the pressure of a long case at the end of a long week. We refuse to release a product before that test.

Once the design is settled, validation begins. Materials testing, dimensional inspection, sterilisation cycle testing, and where applicable, biocompatibility verification. CE, ISO and FDA frameworks dictate the documentation. The product receives a serial trace from raw material through finishing. Nothing leaves the factory without that record.

Even after launch, the loop does not close. Every AVM instrument in active use is a feedback channel. Service requests, sterilisation feedback from CSSDs, surgeon comments at conferences, and observations from our field team feed into our next iteration. Some of our most refined products today look very different from their first commercial version. They have been quietly improved, batch by batch, because we kept listening.

This is what we mean by surgeon-driven innovation. It is not a slogan. It is an operating model in which the surgeon is the source of the brief, the prototype's first user, the validator, and the long-term collaborator. Catalogues do not invent useful instruments. People who pick up instruments and use them on patients invent useful instruments. AVM's job is to make sure the manufacturing line stays close enough to the operating theatre to hear them.